Description

This week we speak to Mr Stephen Shelly again about the exciting but sometimes mysterious world of asthma biologics. We speak about the different biologics, going about getting approval to start an asthma biologic, training, and treatment response.

We speak about the potential impact that asthma biologics are going to have on the future of asthma (and hopefully COPD!), the cost benefit analysis and the limitations of these new wonder drugs.

Chapters

0.42min Intro to Biologics

1.00min Rapid fire round

1.52min Severe asthma & biologic eligibility

3.50min Available biologics

6.50min Which biologic?

7.30min Journey to asthma biologic

13.55min Asthma biologic administration

15.30min Monitoring while on asthma biologic

16.40min Training for asthma biologic admin at home

18.50min Assessing treatment response

21:10min Patient expectations

24:50min Are inhalers still needed?

26:12min Pitfalls in treatment with asthma biologics

28:54min Cost-benefit analysis

31.30min Take-home points

Show notes

Dupilumab https://www.nejm.org/doi/10.1056/NEJMoa1804092

Mepolizumab https://www.nejm.org/doi/10.1056/NEJMoa1403290

Omalizumab https://www.jacionline.org/article/S0091-6749(01)65945-1/fulltext

Benralizumab https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)31322-8/abstractTezepelumab

https://doi.org/10.1164/rccm.202210-2005OC

Difficult to treat asthma (GINA) https://ginasthma.org/wp-content/uploads/2024/11/GINA-Severe-Asthma-Guide-2024-WEB-WMS.pdf

Asthma compliance programmes Ireland https://www.rcsi.com/dublin/research-and-innovation/innovation/investors-entrepreneurs-and-spin-outs/phyxiom